{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:59:35Z","timestamp":1794455975971,"version":"4.9.1"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-023-00486-7","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T04:02:44Z","timestamp":1704340964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":382,"title":["Pulmonary hypertension"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9564-2860","authenticated-orcid":false,"given":"Ana","family":"Mocumbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-0929","authenticated-orcid":false,"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-2030","authenticated-orcid":false,"given":"Friedrich","family":"Thienemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9032-8998","authenticated-orcid":false,"given":"Simon","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"486_CR1","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert, M. et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61, 2200879 (2023).","journal-title":"Eur. Respir. J."},{"key":"486_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","volume":"327","author":"NF Ruopp","year":"2022","unstructured":"Ruopp, N. F. & Cockrill, B. A. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 327, 1379\u20131391 (2022). erratum 328, 892 (2022).","journal-title":"JAMA"},{"key":"486_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert, M. et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 43, 3618\u20133731 (2022).","journal-title":"Eur. Heart J."},{"key":"486_CR4","doi-asserted-by":"crossref","unstructured":"Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 62 (Suppl. 25), D34\u2013D41 (2013); erratum 63, 746 (2014).","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cjca.2015.01.030","volume":"31","author":"AO Mocumbi","year":"2015","unstructured":"Mocumbi, A. O. et al. A global perspective on the epidemiology of pulmonary hypertension. Can. J. Cardiol. 31, 375\u2013381 (2015).","journal-title":"Can. J. Cardiol."},{"key":"486_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2213-2600(18)30268-6","volume":"6","author":"S Rich","year":"2018","unstructured":"Rich, S. et al. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir. Med. 6, 577\u2013579 (2018).","journal-title":"Lancet Respir. Med."},{"key":"486_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijcard.2016.06.242","volume":"221","author":"F Thienemann","year":"2016","unstructured":"Thienemann, F. et al. The causes, treatment, and outcome of pulmonary hypertension in Africa: insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) registry. Int. J. Cardiol. 221, 205\u2013211 (2016).","journal-title":"Int. J. Cardiol."},{"key":"486_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijcard.2018.02.036","volume":"265","author":"S Harikrishnan","year":"2018","unstructured":"Harikrishnan, S. et al. Pulmonary hypertension registry of Kerala, India (PRO-KERALA) \u2013 clinical characteristics and practice patterns. Int. J. Cardiol. 265, 212\u2013217 (2018).","journal-title":"Int. J. Cardiol."},{"key":"486_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/eurjhf\/hfr108","volume":"13","author":"S Stewart","year":"2011","unstructured":"Stewart, S. et al. A not-so-rare form of heart failure in urban black Africans: pathways to right heart failure in the Heart of Soweto Study cohort. Eur. J. Heart Fail. 13, 1070\u20131077 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"486_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/resp.13768","volume":"25","author":"V Khou","year":"2020","unstructured":"Khou, V. et al. Diagnostic delay in pulmonary arterial hypertension, insights from the Australian and New Zealand pulmonary hypertension registry. Respirology 25, 863\u2013871 (2020).","journal-title":"Respirology"},{"key":"486_CR11","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.37765\/ajmc.2021.88609","volume":"27","author":"DJ Levine","year":"2021","unstructured":"Levine, D. J. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am. J. Manag. Care 27, S35\u2013S41 (2021).","journal-title":"Am. J. Manag. Care"},{"key":"486_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12020","volume":"12","author":"S Emmons-Bell","year":"2022","unstructured":"Emmons-Bell, S. et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the Global Burden of Disease 2020 Study. Pulm. Circ. 12, e12020 (2022).","journal-title":"Pulm. Circ."},{"key":"486_CR13","doi-asserted-by":"publisher","first-page":"L992","DOI":"10.1152\/ajplung.00098.2020","volume":"318","author":"PA Corris","year":"2020","unstructured":"Corris, P. A. & Seeger, W. Call it by the correct name \u2013 pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute. Am. J. Physiol. Lung Cell Mol. Physiol. 318, L992\u2013L994 (2020).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"486_CR14","volume":"2020","author":"A Mocumbi","year":"2020","unstructured":"Mocumbi, A. et al. Pulmonary vascular disease in Africa: lessons from registries. Glob. Cardiol. Sci. Pr. 2020, e202002 (2020).","journal-title":"Glob. Cardiol. Sci. Pr."},{"key":"486_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","volume":"173","author":"M Humbert","year":"2006","unstructured":"Humbert, M. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023\u20131030 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1183\/09031936.00092306","volume":"30","author":"AJ Peacock","year":"2007","unstructured":"Peacock, A. J. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30, 104\u2013109 (2007).","journal-title":"Eur. Respir. J."},{"key":"486_CR17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.hlc.2018.02.020","volume":"28","author":"K Haji","year":"2019","unstructured":"Haji, K. et al. Pulmonary hypertension in Central Australia: a community-based cohort study. Heart Lung Circ. 28, 598\u2013604 (2019).","journal-title":"Heart Lung Circ."},{"key":"486_CR18","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1136\/heartjnl-2012-301992","volume":"8","author":"G Strange","year":"2012","unstructured":"Strange, G. et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart 8, 1805\u20131811 (2012).","journal-title":"Heart"},{"key":"486_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003973","volume":"11","author":"DT Wijeratne","year":"2018","unstructured":"Wijeratne, D. T. et al. Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ. Cardiovasc. Qual. Outcomes 11, e003973 (2018).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"486_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","volume":"4","author":"MM Hoeper","year":"2016","unstructured":"Hoeper, M. M. et al. A global view of pulmonary hypertension. Lancet Respir. Med. 4, 306\u2013322 (2016).","journal-title":"Lancet Respir. Med."},{"key":"486_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaccas.2019.11.065","volume":"2","author":"A Sinha","year":"2020","unstructured":"Sinha, A. et al. Heart failure with preserved ejection fraction and obesity: syndrome of cGMP-PKG deficiency in post-menopausal women. JACC Case Rep. 2, 28\u201332 (2020).","journal-title":"JACC Case Rep."},{"key":"486_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1445-5994.2010.02403.x","volume":"41","author":"A Keogh","year":"2011","unstructured":"Keogh, A. et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern. Med. J. 41, 235\u2013244 (2011).","journal-title":"Intern. Med. J."},{"key":"486_CR23","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jacc.2019.03.482","volume":"73","author":"G Strange","year":"2019","unstructured":"Strange, G. et al. Threshold of pulmonary hypertension associated with increased mortality. J. Am. Coll. Cardiol. 73, 2660\u20132672 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","volume":"133","author":"BA Maron","year":"2016","unstructured":"Maron, B. A. et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation 133, 1240\u20131248 (2016).","journal-title":"Circulation"},{"key":"486_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009729","volume":"7","author":"D Kolte","year":"2018","unstructured":"Kolte, D. et al. Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J. Am. Heart Assoc. 7, e009729 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR26","doi-asserted-by":"publisher","first-page":"2100832","DOI":"10.1183\/13993003.00832-2021","volume":"59","author":"S Stewart","year":"2022","unstructured":"Stewart, S. et al. Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography. Eur. Respir. J. 59, 2100832 (2022).","journal-title":"Eur. Respir. J."},{"key":"486_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ihj.2021.12.002","volume":"74","author":"S Harikrishnan","year":"2022","unstructured":"Harikrishnan, S. et al. Pulmonary hypertension registry of Kerala, India (PRO-KERALA): one-year outcomes. Indian Heart J. 74, 34\u201339 (2022).","journal-title":"Indian Heart J."},{"key":"486_CR28","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.hlc.2017.08.018","volume":"27","author":"G Strange","year":"2018","unstructured":"Strange, G. et al. Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand. Heart Lung Circ. 27, 1368\u20131375 (2018).","journal-title":"Heart Lung Circ."},{"key":"486_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ehjci\/jeaa253","volume":"22","author":"D Playford","year":"2021","unstructured":"Playford, D. et al. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA). Eur. Respir. J. Cardiovasc. Imaging 22, 505\u2013515 (2021).","journal-title":"Eur. Respir. J. Cardiovasc. Imaging"},{"key":"486_CR30","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1161\/CIRCULATIONAHA.110.969584","volume":"124","author":"RLE van Loon","year":"2011","unstructured":"van Loon, R. L. E. et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 124, 1755\u20131764 (2011).","journal-title":"Circulation"},{"key":"486_CR31","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1164\/rccm.201406-1052OC","volume":"190","author":"MJ Del Cerro Marin","year":"2014","unstructured":"Del Cerro Marin, M. J. et al. Assessing pulmonary hypertensive vascular disease in childhood, data from the Spanish registry. Am. J. Respir. Crit. Care. Med. 190, 1421\u20131429 (2014).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"486_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/hrt.2009.182378","volume":"96","author":"S Moledina","year":"2010","unstructured":"Moledina, S., Hislop, A. A., Foster, H., Schultze-Neick, I. & Haworth, S. G. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 96, 1401\u20131406 (2010).","journal-title":"Heart"},{"key":"486_CR33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/jcm9061717","volume":"9","author":"J Kwiatkowska","year":"2020","unstructured":"Kwiatkowska, J. et al. Children and adolescents with pulmonary arterial hypertension: baseline and follow-up data from the Polish Registry of Pulmonary Hypertension (BNP-PL). J. Clin. Med. 9, 1717 (2020).","journal-title":"J. Clin. Med."},{"key":"486_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1164\/rccm.202110-2428OC","volume":"206","author":"A Constantine","year":"2022","unstructured":"Constantine, A. et al. Twenty-year experience and outcomes in a national pediatric pulmonary hypertension service. Am. J. Respir. Crit. Care. Med. 206, 758\u2013766 (2022).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"486_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijcard.2009.11.006","volume":"148","author":"AO Mocumbi","year":"2011","unstructured":"Mocumbi, A. O. et al. Challenges on the management of congenital heart disease in developing countries. Int. J. Cardiol. 148, 285\u2013288 (2011).","journal-title":"Int. J. Cardiol."},{"key":"486_CR36","doi-asserted-by":"publisher","first-page":"2003337","DOI":"10.1183\/13993003.03337-2020","volume":"59","author":"SH Abman","year":"2022","unstructured":"Abman, S. H. et al. Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. Eur. Respir. J. 59, 2003337 (2022).","journal-title":"Eur. Respir. J."},{"key":"486_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1086\/690007","volume":"7","author":"L Li","year":"2017","unstructured":"Li, L. et al. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulm. Circ. 7, 126\u2013136 (2017).","journal-title":"Pulm. Circ."},{"key":"486_CR38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1183\/13993003.00211-2016","volume":"48","author":"M Levy","year":"2016","unstructured":"Levy, M. et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur. Respir. J. 48, 1118\u20131126 (2016).","journal-title":"Eur. Respir. J."},{"key":"486_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(11)61621-8","volume":"379","author":"RM Berger","year":"2012","unstructured":"Berger, R. M. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 379, 537\u2013546 (2012).","journal-title":"Lancet"},{"key":"486_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.111.026591","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst, R. J. et al. Survival in childhood pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. Circulation 125, 113\u2013122 (2012).","journal-title":"Circulation"},{"key":"486_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/hrt.2008.150086","volume":"95","author":"SG Haworth","year":"2009","unstructured":"Haworth, S. G. et al. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001\u20132006. Heart 95, 312\u2013317 (2009).","journal-title":"Heart"},{"key":"486_CR42","doi-asserted-by":"publisher","first-page":"2003957","DOI":"10.1183\/13993003.03957-2020","volume":"58","author":"CE Evans","year":"2021","unstructured":"Evans, C. E. et al. Endothelial cells in the pathogenesis of pulmonary arterial hypertension. Eur. Respir. J. 58, 2003957 (2021).","journal-title":"Eur. Respir. J."},{"key":"486_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/CIRCULATIONAHA.117.031258","volume":"138","author":"K-H Chen","year":"2018","unstructured":"Chen, K.-H. et al. Epigenetic dysregulation of the dynamin-related protein 1 binding partners MiD49 and MiD51 increases mitotic mitochondrial fission and promotes pulmonary arterial hypertension, mechanistic and therapeutic implications. Circulation 138, 287\u2013304 (2018).","journal-title":"Circulation"},{"key":"486_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1161\/01.RES.88.6.555","volume":"88","author":"MW Geraci","year":"2001","unstructured":"Geraci, M. W. et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ. Res. 88, 555\u2013562 (2001).","journal-title":"Circ. Res."},{"key":"486_CR45","doi-asserted-by":"publisher","first-page":"225S","DOI":"10.1378\/chest.114.3_Supplement.225S","volume":"114","author":"NF Voelkel","year":"1998","unstructured":"Voelkel, N. F. et al. Primary pulmonary hypertension between inflammation and cancer. Chest 114, 225S\u2013230S (1998).","journal-title":"Chest"},{"key":"486_CR46","doi-asserted-by":"publisher","first-page":"H570","DOI":"10.1152\/ajpheart.01324.2007","volume":"294","author":"SL Archer","year":"2008","unstructured":"Archer, S. L. et al. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1\u03b1-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am. J. Physiol. Heart Circ. Physiol. 294, H570\u2013H578 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"486_CR47","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/CIRCULATIONAHA.108.847707","volume":"121","author":"SL Archer","year":"2010","unstructured":"Archer, S. L. et al. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121, 2045\u20132066 (2010).","journal-title":"Circulation"},{"key":"486_CR48","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan, T. et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360, j5492 (2018).","journal-title":"BMJ"},{"key":"486_CR49","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1164\/rccm.202006-2169OC","volume":"203","author":"J Hong","year":"2021","unstructured":"Hong, J. et al. Single-cell study of two rat models of pulmonary arterial hypertension reveals connections to human pathobiology and drug repositioning. Am. J. Respir. Crit. Care Med. 203, 1006\u20131022 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR50","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3390\/ijms19092730","volume":"19","author":"F Potus","year":"2018","unstructured":"Potus, F. et al. Transcriptomic signature of right ventricular failure in experimental pulmonary arterial hypertension: deep sequencing demonstrates mitochondrial, fibrotic, inflammatory and angiogenic abnormalities. Int. J. Mol. Sci. 19, 2730 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"486_CR51","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s44161-022-00113-w","volume":"1","author":"O Boucherat","year":"2022","unstructured":"Boucherat, O. et al. Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. Nat. Cardiovasc. Res. 1, 748\u2013760 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"486_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00891-1","volume":"13","author":"N Zhu","year":"2021","unstructured":"Zhu, N. et al. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med. 13, 80 (2021).","journal-title":"Genome Med."},{"key":"486_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/303059","volume":"67","author":"Z Deng","year":"2000","unstructured":"Deng, Z. et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67, 737\u2013744 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"486_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","volume":"26","author":"KB Lane","year":"2000","unstructured":"Lane, K. B. et al. Heterozygous germline mutations in BMPR2, encoding a TGF-\u03b2 receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26, 81\u201384 (2000).","journal-title":"Nat. Genet."},{"key":"486_CR55","doi-asserted-by":"publisher","first-page":"2201471","DOI":"10.1183\/13993003.01471-2022","volume":"61","author":"CA Eichstaedt","year":"2023","unstructured":"Eichstaedt, C. A. et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur. Respir. J. 61, 2201471 (2023).","journal-title":"Eur. Respir. J."},{"key":"486_CR56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1378\/chest.13-2366","volume":"145","author":"DH Best","year":"2014","unstructured":"Best, D. H. et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 145, 231\u2013236 (2014).","journal-title":"Chest"},{"key":"486_CR57","doi-asserted-by":"publisher","first-page":"2004229","DOI":"10.1183\/13993003.04229-2020","volume":"58","author":"DG Montani","year":"2021","unstructured":"Montani, D. G. et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur. Respir. J 58, 2004229 (2021).","journal-title":"Eur. Respir. J"},{"key":"486_CR58","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert, M. et al. Sotatercept for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 384, 1204\u20131215 (2021).","journal-title":"N. Engl. J. Med."},{"key":"486_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/2045-8932.87300","volume":"1","author":"GH Kim","year":"2011","unstructured":"Kim, G. H. et al. Epigenetic mechanisms of pulmonary hypertension. Pulm. Circ. 1, 347\u2013356 (2011).","journal-title":"Pulm. Circ."},{"key":"486_CR60","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.00078.2019","volume":"318","author":"S Bonnet","year":"2020","unstructured":"Bonnet, S. et al. Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. Am. J. Physiol. Cell Physiol. 318, C1\u2013C28 (2020).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"486_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91327","volume":"2","author":"V Negi","year":"2017","unstructured":"Negi, V. & Chan, S. Y. Discerning functional hierarchies of microRNAs in pulmonary hypertension. JCI Insight 2, e91327 (2017).","journal-title":"JCI Insight"},{"key":"486_CR62","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.115.016382","volume":"132","author":"F Potus","year":"2015","unstructured":"Potus, F. et al. Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 132, 932\u2013943 (2015).","journal-title":"Circulation"},{"key":"486_CR63","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","volume":"95","author":"MS McMurtry","year":"2004","unstructured":"McMurtry, M. S. et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95, 830\u2013840 (2004).","journal-title":"Circ. Res."},{"key":"486_CR64","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1161\/CIRCULATIONAHA.109.916098","volume":"121","author":"SL Archer","year":"2010","unstructured":"Archer, S. L. et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121, 2661\u20132671 (2010).","journal-title":"Circulation"},{"key":"486_CR65","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.119.044320","volume":"141","author":"F Potus","year":"2020","unstructured":"Potus, F. et al. Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension. Circulation 141, 1986\u20132000 (2020).","journal-title":"Circulation"},{"key":"486_CR66","doi-asserted-by":"publisher","unstructured":"Hindmarch C. C. T. et al. Humans with pulmonary arterial hypertension display a global hypermethylation signature that worsens in patients who have a mutation in the gene encoding the methylation eraser, Tet methylcytosine dioxygenase 2 (TET2). Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.08.09.23293846 (2023).","DOI":"10.1101\/2023.08.09.23293846"},{"key":"486_CR67","doi-asserted-by":"publisher","first-page":"15081","DOI":"10.1074\/jbc.M702679200","volume":"282","author":"S de Frutos","year":"2007","unstructured":"de Frutos, S. et al. NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with \u03b1-actin up-regulation. J. Biol. Chem. 282, 15081\u201315089 (2007).","journal-title":"J. Biol. Chem."},{"key":"486_CR68","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1073\/pnas.0610467104","volume":"104","author":"S Bonnet","year":"2007","unstructured":"Bonnet, S. et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl Acad. Sci. USA 104, 11418\u201311423 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"486_CR69","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000492852","volume":"49","author":"RL He","year":"2018","unstructured":"He, R. L. et al. Calcineurin\/NFAT signaling modulates pulmonary artery smooth muscle cell proliferation, migration and apoptosis in monocrotaline-induced pulmonary arterial hypertension rats. Cell Physiol. Biochem. 49, 172\u2013189 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"486_CR70","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1172\/JCI74773","volume":"124","author":"T Bertero","year":"2014","unstructured":"Bertero, T. et al. Systems-level regulation of microRNA networks by miR-130\/301 promotes pulmonary hypertension. J. Clin. Invest. 124, 3514\u20133528 (2014).","journal-title":"J. Clin. Invest."},{"key":"486_CR71","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911303","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. MicroRNA-483 amelioration of experimental pulmonary hypertension. EMBO Mol. Med. 12, e11303 (2020).","journal-title":"EMBO Mol. Med."},{"key":"486_CR72","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1164\/rccm.202009-3419OC","volume":"203","author":"L Hu","year":"2021","unstructured":"Hu, L. et al. YTHDF1 regulates pulmonary hypertension through translational control of MAGED1. Am. J. Respir. Crit. Care Med. 203, 1158\u20131172 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR73","doi-asserted-by":"publisher","first-page":"119366","DOI":"10.1016\/j.lfs.2021.119366","volume":"274","author":"Y Qin","year":"2021","unstructured":"Qin, Y. et al. The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension. Life Sci. 274, 119366 (2021).","journal-title":"Life Sci."},{"key":"486_CR74","doi-asserted-by":"publisher","first-page":"18238","DOI":"10.18632\/aging.203230","volume":"13","author":"Y Zeng","year":"2021","unstructured":"Zeng, Y. et al. Integrated analysis of m6A mRNA methylation in rats with monocrotaline-induced pulmonary arterial hypertension. Aging 13, 18238\u201318256 (2021).","journal-title":"Aging"},{"key":"486_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.112.103176","volume":"126","author":"L Zhao","year":"2012","unstructured":"Zhao, L. et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455\u2013467 (2012).","journal-title":"Circulation"},{"key":"486_CR76","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI23203","volume":"115","author":"MS McMurtry","year":"2005","unstructured":"McMurtry, M. S. et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115, 1479\u20131491 (2005).","journal-title":"J. Clin. Invest."},{"key":"486_CR77","doi-asserted-by":"publisher","first-page":"L124","DOI":"10.1152\/ajplung.00263.2015","volume":"311","author":"E Nozik-Grayck","year":"2016","unstructured":"Nozik-Grayck, E. et al. Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 311, L124\u2013L134 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"486_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cmet.2014.01.004","volume":"19","author":"G Sutendra","year":"2014","unstructured":"Sutendra, G. & Michelakis, E. D. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 19, 558\u2013573 (2014).","journal-title":"Cell Metab."},{"key":"486_CR79","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tibs.2016.01.004","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 287 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"486_CR80","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1164\/rccm.201108-1562OC","volume":"185","author":"G Marsboom","year":"2012","unstructured":"Marsboom, G. et al. Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 185, 670\u2013679 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR81","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.113.004136","volume":"128","author":"L Zhao","year":"2013","unstructured":"Zhao, L. et al. Heterogeneity in lung 18FDG uptake in pulmonary arterial hypertension: potential of dynamic 18FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 128, 1214\u20131224 (2013).","journal-title":"Circulation"},{"key":"486_CR82","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.jacc.2005.02.065","volume":"45","author":"M Oikawa","year":"2005","unstructured":"Oikawa, M. et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J. Am. Coll. Cardiol. 45, 1849\u20131855 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR83","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.3390\/ijms21197278","volume":"21","author":"SZ Prisco","year":"2020","unstructured":"Prisco, S. Z. et al. Excess protein O-GlcNAcylation links metabolic derangements to right ventricular dysfunction in pulmonary arterial hypertension. Int. J. Mol. Sci. 21, 7278 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"486_CR84","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00109-012-0982-0","volume":"91","author":"L Piao","year":"2013","unstructured":"Piao, L. et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J. Mol. Med. 91, 333\u2013346 (2013).","journal-title":"J. Mol. Med."},{"key":"486_CR85","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1161\/CIRCULATIONAHA.116.021494","volume":"133","author":"Z Dai","year":"2016","unstructured":"Dai, Z. et al. Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2\u03b1. Circulation 133, 2447\u20132458 (2016).","journal-title":"Circulation"},{"key":"486_CR86","doi-asserted-by":"publisher","first-page":"2102643","DOI":"10.1183\/13993003.02643-2021","volume":"60","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension. Eur. Respir. J. 60, 2102643 (2022).","journal-title":"Eur. Respir. J."},{"key":"486_CR87","doi-asserted-by":"publisher","first-page":"eaao4583","DOI":"10.1126\/scitranslmed.aao4583","volume":"9","author":"ED Michelakis","year":"2017","unstructured":"Michelakis, E. D. et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci. Transl. Med. 9, eaao4583 (2017).","journal-title":"Sci. Transl. Med."},{"key":"486_CR88","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.117.028034","volume":"136","author":"P Caruso","year":"2017","unstructured":"Caruso, P. et al. Identification of microRNA-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (polypyrimidine tract binding protein) and pyruvate kinase M2. Circulation 136, 2451\u20132467 (2017).","journal-title":"Circulation"},{"key":"486_CR89","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1161\/CIRCULATIONAHA.117.028069","volume":"136","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124\/PTBP1 (polypyrimidine tract binding protein 1)\/pyruvate kinase muscle axis. Circulation 136, 2468\u20132485 (2017).","journal-title":"Circulation"},{"key":"486_CR90","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","volume":"1","author":"PJ Randle","year":"1963","unstructured":"Randle, P. J. et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785\u2013789 (1963).","journal-title":"Lancet"},{"key":"486_CR91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","volume":"90","author":"YH Fang","year":"2012","unstructured":"Fang, Y. H. et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy, exploiting Randle\u2019s cycle. J. Mol. Med. 90, 31\u201343 (2012).","journal-title":"J. Mol. Med."},{"key":"486_CR92","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1086\/682427","volume":"5","author":"SS Khan","year":"2015","unstructured":"Khan, S. S. et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm. Circ. 5, 547\u2013556 (2015).","journal-title":"Pulm. Circ."},{"key":"486_CR93","doi-asserted-by":"publisher","first-page":"L355","DOI":"10.1152\/ajplung.00039.2022","volume":"323","author":"MH Lee","year":"2022","unstructured":"Lee, M. H. et al. Contribution of fatty acid oxidation to the pathogenesis of pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 323, L355\u2013L371 (2022).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"486_CR94","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.115.019351","volume":"133","author":"EL Brittain","year":"2016","unstructured":"Brittain, E. L. et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation 133, 1936\u20131944 (2016).","journal-title":"Circulation"},{"key":"486_CR95","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00109-013-1064-7","volume":"91","author":"L Piao","year":"2013","unstructured":"Piao, L. et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J. Mol. Med. 91, 1185\u20131197 (2013).","journal-title":"J. Mol. Med."},{"key":"486_CR96","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1753-4887.1990.tb02967.x","volume":"48","author":"JM Lacey","year":"1990","unstructured":"Lacey, J. M. & Wilmore, D. W. Is glutamine a conditionally essential amino acid? Nutr. Rev. 48, 297\u2013309 (1990).","journal-title":"Nutr. Rev."},{"key":"486_CR97","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019091","volume":"10","author":"AP Acharya","year":"2021","unstructured":"Acharya, A. P. et al. Simultaneous pharmacologic inhibition of yes-associated protein 1 and glutaminase 1 via inhaled poly(lactic-co-glycolic) acid-encapsulated microparticles improves pulmonary hypertension. J. Am. Heart Assoc. 10, e019091 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR98","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1172\/JCI86387","volume":"126","author":"T Bertero","year":"2016","unstructured":"Bertero, T. et al. Vascular stiffness mechanoactivates YAP\/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J. Clin. Invest. 126, 3313\u20133335 (2016).","journal-title":"J. Clin. Invest."},{"key":"486_CR99","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1056\/NEJMra1215233","volume":"369","author":"SL Archer","year":"2013","unstructured":"Archer, S. L. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N. Engl. J. Med. 369, 2236\u20132251 (2013).","journal-title":"N. Engl. J. Med."},{"key":"486_CR100","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCRESAHA.111.263848","volume":"110","author":"G Marsboom","year":"2012","unstructured":"Marsboom, G. et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ. Res 110, 1484\u20131497 (2012).","journal-title":"Circ. Res"},{"key":"486_CR101","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1096\/fj.11-196543","volume":"26","author":"J Rehman","year":"2012","unstructured":"Rehman, J. et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 26, 2175\u20132186 (2012).","journal-title":"FASEB J."},{"key":"486_CR102","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1164\/rccm.201209-1687OC","volume":"187","author":"JJ Ryan","year":"2013","unstructured":"Ryan, J. J. et al. PGC1\u03b1-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 187, 865\u2013878 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR103","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","volume":"190","author":"MO Becker","year":"2014","unstructured":"Becker, M. O. et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am. J. Respir. Crit. Care Med. 190, 808\u2013817 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR104","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014201","volume":"8","author":"H Qiu","year":"2019","unstructured":"Qiu, H. et al. The role of regulatory T cells in pulmonary arterial hypertension. J. Am. Heart Assoc. 8, e014201 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR105","doi-asserted-by":"publisher","first-page":"908783","DOI":"10.3389\/fphar.2022.908783","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Regulatory T cell-related gene indicators in pulmonary hypertension. Front. Pharmacol. 13, 908783 (2022).","journal-title":"Front. Pharmacol."},{"key":"486_CR106","doi-asserted-by":"publisher","first-page":"684657","DOI":"10.3389\/fimmu.2021.684657","volume":"12","author":"W Tian","year":"2021","unstructured":"Tian, W. et al. The role of regulatory T cells in pulmonary arterial hypertension. Front. Immunol. 12, 684657 (2021).","journal-title":"Front. Immunol."},{"key":"486_CR107","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1164\/rccm.202110-2274OC","volume":"206","author":"R Al-Qazazi","year":"2022","unstructured":"Al-Qazazi, R. et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 206, 608\u2013624 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR108","doi-asserted-by":"publisher","first-page":"200ra117","DOI":"10.1126\/scitranslmed.3006674","volume":"5","author":"W Tian","year":"2013","unstructured":"Tian, W. et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci. Transl. Med. 5, 200ra117 (2013).","journal-title":"Sci. Transl. Med."},{"key":"486_CR109","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1161\/CIRCULATIONAHA.112.110619","volume":"126","author":"ML Ormiston","year":"2012","unstructured":"Ormiston, M. L. et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation 126, 1099\u20131109 (2012).","journal-title":"Circulation"},{"key":"486_CR110","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra050002","volume":"353","author":"EK Weir","year":"2005","unstructured":"Weir, E. K. et al. Acute oxygen-sensing mechanisms. N. Engl. J. Med. 353, 2042\u20132055 (2005).","journal-title":"N. Engl. J. Med."},{"key":"486_CR111","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0140-6736(05)78495-6","volume":"351","author":"XJ Yuan","year":"1998","unstructured":"Yuan, X. J. et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351, 726\u2013727 (1998).","journal-title":"Lancet"},{"key":"486_CR112","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1096\/fasebj.9.2.7781921","volume":"9","author":"EK Weir","year":"1995","unstructured":"Weir, E. K. & Archer, S. L. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J. 9, 183\u2013189 (1995).","journal-title":"FASEB J."},{"key":"486_CR113","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1172\/JCI333","volume":"101","author":"SL Archer","year":"1998","unstructured":"Archer, S. L. et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J. Clin. Invest. 101, 2319\u20132330 (1998).","journal-title":"J. Clin. Invest."},{"key":"486_CR114","doi-asserted-by":"publisher","first-page":"L801","DOI":"10.1152\/ajplung.2001.280.4.L801","volume":"280","author":"O Platoshyn","year":"2001","unstructured":"Platoshyn, O. et al. Chronic hypoxia decreases KV channel expression and function in pulmonary artery myocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L801\u2013L812 (2001).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"486_CR115","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/01.CIR.0000062688.76508.B3","volume":"107","author":"ZI Pozeg","year":"2003","unstructured":"Pozeg, Z. I. et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107, 2037\u20132044 (2003).","journal-title":"Circulation"},{"key":"486_CR116","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/0006-291X(77)91429-2","volume":"78","author":"R Dabrowska","year":"1977","unstructured":"Dabrowska, R. et al. Composition of the myosin light chain kinase from chicken gizzard. Biochem. Biophys. Res. Commun. 78, 1263\u20131272 (1977).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"486_CR117","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/40187","volume":"389","author":"M Uehata","year":"1997","unstructured":"Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990\u2013994 (1997).","journal-title":"Nature"},{"key":"486_CR118","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa1211097","volume":"369","author":"L Ma","year":"2013","unstructured":"Ma, L. et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med. 369, 351\u2013361 (2013).","journal-title":"N. Engl. J. Med."},{"key":"486_CR119","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/01.CIR.98.14.1400","volume":"98","author":"JX Yuan","year":"1998","unstructured":"Yuan, J. X. et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98, 1400\u20131406 (1998).","journal-title":"Circulation"},{"key":"486_CR120","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1038\/sj.bjp.0707635","volume":"153","author":"ED Burg","year":"2008","unstructured":"Burg, E. D. et al. Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br. J. Pharmacol. 153, S99\u2013S111 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"486_CR121","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon, O. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111, 3105\u20133111 (2005).","journal-title":"Circulation"},{"key":"486_CR122","first-page":"1898","volume":"31","author":"D Montani","year":"2010","unstructured":"Montani, D. et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur. Respir. J. 31, 1898\u20131907 (2010).","journal-title":"Eur. Respir. J."},{"key":"486_CR123","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.bbamcr.2017.06.018","volume":"1864","author":"S Sankhe","year":"2017","unstructured":"Sankhe, S. et al. T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A\/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. Biochim. Biophys. Acta Mol. Cell. Res. 1864, 1631\u20131641 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"486_CR124","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/biom11121781","volume":"11","author":"B Masson","year":"2021","unstructured":"Masson, B. et al. Role of store-operated Ca2+ entry in the pulmonary vascular remodeling occurring in pulmonary arterial hypertension. Biomolecules 11, 1781 (2021).","journal-title":"Biomolecules"},{"key":"486_CR125","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/HYPERTENSIONAHA.117.10503","volume":"71","author":"S Song","year":"2018","unstructured":"Song, S. et al. STIM2 (stromal interaction molecule 2)-mediated increase in resting cytosolic free Ca2+ concentration stimulates PASMC proliferation in pulmonary arterial hypertension. Hypertension 71, 518\u2013529 (2018).","journal-title":"Hypertension"},{"key":"486_CR126","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.113.001585","volume":"128","author":"L Hadri","year":"2013","unstructured":"Hadri, L. et al. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 128, 512\u2013523 (2013).","journal-title":"Circulation"},{"key":"486_CR127","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0331-8","volume":"559","author":"R Baradaran","year":"2018","unstructured":"Baradaran, R. et al. Cryo-EM structures of fungal and metazoan mitochondrial calcium uniporters. Nature 559, 580\u2013584 (2018).","journal-title":"Nature"},{"key":"486_CR128","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1164\/rccm.201604-0814OC","volume":"195","author":"Z Hong","year":"2017","unstructured":"Hong, Z. et al. MicroRNA-138 and microRNA-25 down-regulate mitochondrial calcium uniporter, causing the pulmonary arterial hypertension cancer phenotype. Am. J. Respir. Crit. Care Med. 195, 515\u2013529 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR129","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1042\/bst0210793","volume":"21","author":"JG McCormack","year":"1993","unstructured":"McCormack, J. G. & Denton, R. M. The role of intramitochondrial Ca2+ in the regulation of oxidative phosphorylation in mammalian tissues. Biochem. Soc. Trans. 21, 793\u2013799 (1993).","journal-title":"Biochem. Soc. Trans."},{"key":"486_CR130","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1164\/rccm.200805-691OC","volume":"179","author":"C Guilluy","year":"2009","unstructured":"Guilluy, C. et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care Med. 179, 1151\u20131158 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR131","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/hr.2015.33","volume":"38","author":"R Jiang","year":"2015","unstructured":"Jiang, R. et al. Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertens. Res. 38, 539\u2013544 (2015).","journal-title":"Hypertens. Res."},{"key":"486_CR132","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","volume":"26","author":"M Nootens","year":"1995","unstructured":"Nootens, M. et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J. Am. Coll. Cardiol. 26, 1581\u20131585 (1995).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR133","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1161\/CIRCULATIONAHA.112.109868","volume":"126","author":"L Piao","year":"2012","unstructured":"Piao, L. et al. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 126, 2859\u20132869 (2012).","journal-title":"Circulation"},{"key":"486_CR134","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1172\/JCI115659","volume":"89","author":"MR Bristow","year":"1992","unstructured":"Bristow, M. R. et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J. Clin. Invest. 89, 803\u2013815 (1992).","journal-title":"J. Clin. Invest."},{"key":"486_CR135","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021518","volume":"10","author":"T Thenappan","year":"2021","unstructured":"Thenappan, T., Weir, E. K., Prins, K. W., Pritzker, M. R. & Archer, S. L. Carvedilol for treatment of right ventricular dysfunction in pulmonary arterial hypertension. J. Am. Heart Assoc. 10, e021518 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR136","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/09059180.00006511","volume":"20","author":"A Vonk Noordegraaf","year":"2011","unstructured":"Vonk Noordegraaf, A. & Galli\u00e8, N. The role of the right ventricle in pulmonary arterial hypertension. Eur. Respir. Rev. 20, 243\u2013253 (2011).","journal-title":"Eur. Respir. Rev."},{"key":"486_CR137","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cjca.2015.01.023","volume":"31","author":"JJ Ryan","year":"2015","unstructured":"Ryan, J. J. et al. Right ventricular adaptation and failure in pulmonary arterial hypertension. Can. J. Cardiol. 31, 391\u2013406 (2015).","journal-title":"Can. J. Cardiol."},{"key":"486_CR138","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1183\/09031936.00135407","volume":"31","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek, M. J. et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur. Respir. J. 31, 1160\u20131166 (2008).","journal-title":"Eur. Respir. J."},{"key":"486_CR139","first-page":"100","volume":"15","author":"WE Hopkins","year":"1996","unstructured":"Hopkins, W. E. et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J. Heart Lung Transpl. 15, 100\u2013105 (1996).","journal-title":"J. Heart Lung Transpl."},{"key":"486_CR140","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1378\/chest.13-1291","volume":"145","author":"W Jacobs","year":"2014","unstructured":"Jacobs, W. et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest 145, 1230\u20131236 (2014).","journal-title":"Chest"},{"key":"486_CR141","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza, R. L. et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122, 164\u2013172 (2010).","journal-title":"Circulation"},{"key":"486_CR142","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","volume":"122","author":"M Humbert","year":"2020","unstructured":"Humbert, M. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122, 156\u2013163 (2020).","journal-title":"Circulation"},{"key":"486_CR143","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2214\/AJR.09.4114","volume":"196","author":"ML Shehata","year":"2011","unstructured":"Shehata, M. L. et al. Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am. J. Roentgenol. 196, 87\u201394 (2011).","journal-title":"AJR Am. J. Roentgenol."},{"key":"486_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13483","volume":"229","author":"L Tian","year":"2020","unstructured":"Tian, L. et al. Supra-coronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion. Acta Physiol. 229, e13483 (2020).","journal-title":"Acta Physiol."},{"key":"486_CR145","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00109-017-1522-8","volume":"95","author":"L Tian","year":"2017","unstructured":"Tian, L. et al. Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. J. Mol. Med. 95, 381\u2013393 (2017).","journal-title":"J. Mol. Med."},{"key":"486_CR146","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.120.316443","volume":"126","author":"L Tian","year":"2020","unstructured":"Tian, L. et al. Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension: a pyruvate dehydrogenase kinase-dependent shift in mitochondrial metabolism promotes right ventricular fibrosis. Circ. Res. 126, 1723\u20131745 (2020).","journal-title":"Circ. Res."},{"key":"486_CR147","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCRESAHA.114.301633","volume":"114","author":"D Wang","year":"2014","unstructured":"Wang, D. et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ. Res. 114, 67\u201378 (2014).","journal-title":"Circ. Res."},{"key":"486_CR148","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.healun.2017.08.011","volume":"37","author":"KW Prins","year":"2018","unstructured":"Prins, K. W. et al. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J. Heart Lung Transpl. 37, 376\u2013384 (2018).","journal-title":"J. Heart Lung Transpl."},{"key":"486_CR149","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","volume":"88","author":"L Piao","year":"2010","unstructured":"Piao, L. et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J. Mol. Med. 88, 47\u201360 (2010).","journal-title":"J. Mol. Med."},{"key":"486_CR150","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1161\/CIRCULATIONAHA.105.609008","volume":"113","author":"S Bonnet","year":"2006","unstructured":"Bonnet, S. et al. An abnormal mitochondrial-hypoxia inducible factor-1\u03b1-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113, 2630\u20132641 (2006).","journal-title":"Circulation"},{"key":"486_CR151","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/hc0202.101974","volume":"105","author":"ED Michelakis","year":"2002","unstructured":"Michelakis, E. D. et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105, 244\u2013250 (2002).","journal-title":"Circulation"},{"key":"486_CR152","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006195","volume":"6","author":"KW Prins","year":"2017","unstructured":"Prins, K. W. et al. Colchicine depolymerizes microtubules, increases junctophilin-2, and improves right ventricular function in experimental pulmonary arterial hypertension. J. Am. Heart Assoc. 6, e006195 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR153","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1164\/rccm.201003-0335OC","volume":"182","author":"HJ Bogaard","year":"2010","unstructured":"Bogaard, H. J. et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am. J. Respir. Crit. Care Med. 182, 652\u2013660 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR154","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1165\/rcmb.2018-0095OC","volume":"59","author":"BB Graham","year":"2018","unstructured":"Graham, B. B. et al. Vascular adaptation of the right ventricle in experimental pulmonary hypertension. Am. J. Respir. Cell. Mol. Biol. 59, 479\u2013489 (2018).","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"486_CR155","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.202109-2079PP","volume":"205","author":"CD Vizza","year":"2022","unstructured":"Vizza, C. D. et al. Aggressive afterload lowering to improve the right ventricle: a new target for medical therapy in pulmonary arterial hypertension? Am. J. Respir. Crit. Care Med. 205, 751\u2013760 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR156","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/rheumatology\/kead103","volume":"62","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. 10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry. Rheumatology 62, 3555\u20133564 (2023).","journal-title":"Rheumatology"},{"key":"486_CR157","doi-asserted-by":"publisher","first-page":"190050","DOI":"10.1183\/16000617.0050-2019","volume":"28","author":"K Swinnen","year":"2019","unstructured":"Swinnen, K. et al. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur. Respir. Rev. 28, 190050 (2019).","journal-title":"Eur. Respir. Rev."},{"key":"486_CR158","volume":"2020","author":"M Idrees","year":"2020","unstructured":"Idrees, M. et al. Pulmonary hypertension in the developing world: local registries, challenges, and ways to move forward. Glob. Cardiol. Sci. Pract. 2020, e202014 (2020).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"486_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2023.08.004","author":"K Kubota","year":"2023","unstructured":"Kubota, K. et al. Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis. J. Cardiol.\u00a0https:\/\/doi.org\/10.1016\/j.jjcc.2023.08.004 (2023).","journal-title":"J. Cardiol."},{"key":"486_CR160","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12890-018-0667-8","volume":"18","author":"AB Valverde","year":"2018","unstructured":"Valverde, A. B. et al. Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulm. Med. 18, 106 (2018).","journal-title":"BMC Pulm. Med."},{"key":"486_CR161","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3899\/jrheum.130400","volume":"40","author":"H Gladue","year":"2013","unstructured":"Gladue, H. et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J. Rheumatol. 40, 1706\u20131711 (2013).","journal-title":"J. Rheumatol."},{"key":"486_CR162","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jjcc.2023.01.005","volume":"82","author":"S Ishii","year":"2023","unstructured":"Ishii, S. et al. Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension. J. Cardiol. 82, 69\u201375 (2023).","journal-title":"J. Cardiol."},{"key":"486_CR163","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1148\/radiographics.22.4.g02jl01739","volume":"22","author":"C Engelke","year":"2002","unstructured":"Engelke, C. et al. High-resolution CT and CT angiography of peripheral pulmonary vascular disorders. Radiographics 22, 739\u2013764 (2002).","journal-title":"Radiographics"},{"key":"486_CR164","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/thoraxjnl-2014-206088","volume":"70","author":"S Rajaram","year":"2015","unstructured":"Rajaram, S. et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax 70, 382\u2013387 (2015).","journal-title":"Thorax"},{"key":"486_CR165","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/children9081217","volume":"9","author":"YC Liu","year":"2022","unstructured":"Liu, Y. C. et al. Long-term study on therapeutic strategy for treatment of Eisenmenger syndrome patients: a case series study. Children 9, 1217 (2022).","journal-title":"Children"},{"key":"486_CR166","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1053\/pcad.2002.127492","volume":"45","author":"EB Berman","year":"2002","unstructured":"Berman, E. B. & Barst, R. J. Eisenmenger\u2019s syndrome: current management. Prog. Cardiovasc. Dis. 45, 129\u2013138 (2002).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"486_CR167","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijcard.2015.08.155","volume":"202","author":"JM Douwes","year":"2016","unstructured":"Douwes, J. M. et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. Int. J. Cardiol. 202, 34\u201339 (2016).","journal-title":"Int. J. Cardiol."},{"key":"486_CR168","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2015.01.038","volume":"184","author":"MJ Ploegstra","year":"2015","unstructured":"Ploegstra, M. J. et al. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int. J. Cardiol. 184, 198\u2013207 (2015).","journal-title":"Int. J. Cardiol."},{"key":"486_CR169","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00246-015-1100-1","volume":"36","author":"P Bobhate","year":"2015","unstructured":"Bobhate, P. et al. Cardiac catheterization in children with pulmonary hypertensive vascular disease. Pediatr. Cardiol. 36, 873\u2013879 (2015).","journal-title":"Pediatr. Cardiol."},{"key":"486_CR170","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jacc.2015.07.032","volume":"66","author":"ML O\u2019Byrne","year":"2015","unstructured":"O\u2019Byrne, M. L. et al. Predictors of catastrophic adverse outcomes in children with pulmonary hypertension undergoing cardiac catheterization: a multi-institutional analysis from the Pediatric Health Information Systems Database. J. Am. Coll. Cardiol. 66, 1261\u20131269 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR171","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029085","volume":"12","author":"J Grynblat","year":"2023","unstructured":"Grynblat, J. et al. Monitoring of hemodynamics with right heart catheterization in children with pulmonary arterial hypertension. J. Am. Heart Assoc. 12, e029085 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"486_CR172","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012049","volume":"8","author":"BS Hasan","year":"2023","unstructured":"Hasan, B. S. et al. Recommendations for developing effective and safe paediatric and congenital heart disease services in low-income and middle-income countries: a public health framework. BMJ Glob. Health 8, e012049 (2023).","journal-title":"BMJ Glob. Health"},{"key":"486_CR173","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5830\/CVJA-2018-042","volume":"30","author":"A Dzudie","year":"2019","unstructured":"Dzudie, A. et al. A diagnostic algorithm for pulmonary hypertension due to left heart disease in resource-limited settings: can busy clinicians adopt a simple, practical approach? Cardiovasc. J. Afr. 30, 61\u201367 (2019).","journal-title":"Cardiovasc. J. Afr."},{"key":"486_CR174","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/adc.2007.123653","volume":"93","author":"AE Lammers","year":"2008","unstructured":"Lammers, A. E. et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch. Dis. Child. 93, 464\u2013468 (2008).","journal-title":"Arch. Dis. Child."},{"key":"486_CR175","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41569-019-0268-0","volume":"16","author":"S Stewart","year":"2019","unstructured":"Stewart, S. et al. Clinical algorithm to screen for cardiopulmonary disease in low-income settings. Nat. Rev. Cardiol. 16, 639\u2013641 (2019).","journal-title":"Nat. Rev. Cardiol."},{"key":"486_CR176","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. The global burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol. 80, 2361\u20132371 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR177","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jch.12610","volume":"17","author":"JJ Noubiap","year":"2015","unstructured":"Noubiap, J. J. et al. Targeting household air pollution for curbing the cardiovascular disease burden: a health priority in sub-Saharan Africa. J. Clin. Hypertens. 17, 825\u2013829 (2015).","journal-title":"J. Clin. Hypertens."},{"key":"486_CR178","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/MCP.0b013e3283218304","volume":"15","author":"G Hu","year":"2009","unstructured":"Hu, G. & Ran, P. Indoor air pollution as a lung health hazard: focus on populous countries. Curr. Opin. Pulm. Med. 15, 158\u2013164 (2009).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"486_CR179","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1161\/CIRCULATIONAHA.110.992362","volume":"123","author":"K Sliwa","year":"2011","unstructured":"Sliwa, K. et al. Hypertension: a global perspective. Circulation 123, 2892\u20132896 (2011).","journal-title":"Circulation"},{"key":"486_CR180","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s40572-019-00234-8","volume":"6","author":"AO Mocumbi","year":"2019","unstructured":"Mocumbi, A. O. et al. Cardiovascular effects of indoor air pollution from solid fuel: relevance to sub-Saharan Africa. Curr. Environ. Health Rep. 6, 116\u2013126 (2019).","journal-title":"Curr. Environ. Health Rep."},{"key":"486_CR181","doi-asserted-by":"publisher","first-page":"9998070","DOI":"10.1155\/2021\/9998070","volume":"2021","author":"J Namuyonga","year":"2021","unstructured":"Namuyonga, J. & Mocumbi, A. O. Pulmonary hypertension in children across Africa, the silent threat. Int. J. Pediatr. 2021, 9998070 (2021).","journal-title":"Int. J. Pediatr."},{"key":"486_CR182","doi-asserted-by":"publisher","first-page":"RA31","DOI":"10.12659\/MSM.882607","volume":"18","author":"R Patel","year":"2012","unstructured":"Patel, R. et al. Treatment of pulmonary hypertension. Med. Sci. Monit. 18, RA31\u2013RA39 (2012).","journal-title":"Med. Sci. Monit."},{"key":"486_CR183","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1061186X.2023.2199351","volume":"31","author":"H Tanvirul","year":"2023","unstructured":"Tanvirul, H. et al. Emerging biologics for the treatment of pulmonary arterial hypertension. J. Drug Target. 31, 471\u2013485 (2023).","journal-title":"J. Drug Target."},{"key":"486_CR184","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478\u20131490 (2023).","journal-title":"N. Engl. J. Med."},{"key":"486_CR185","doi-asserted-by":"publisher","first-page":"170095","DOI":"10.1183\/16000617.0095-2017","volume":"26","author":"S Gaine","year":"2017","unstructured":"Gaine, S. & McLaughlin, V. Pulmonary arterial hypertension: tailoring treatment to risk in the current era. Eur. Respir. Rev. 26, 170095 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"486_CR186","doi-asserted-by":"publisher","first-page":"7136","DOI":"10.3390\/jcm11237136","volume":"11","author":"M Toma","year":"2022","unstructured":"Toma, M. et al. Left heart disease phenotype in elderly patients with pulmonary arterial hypertension: insights from the Italian PATRIARCA registry. J. Clin. Med.\u00a011, 7136 (2022).","journal-title":"J. Clin. Med."},{"key":"486_CR187","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S2213-2600(22)00097-2","volume":"10","author":"MM Hoeper","year":"2022","unstructured":"Hoeper, M. M. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir. Med. 10, 937\u2013948 (2022).","journal-title":"Lancet Respir. Med."},{"key":"486_CR188","doi-asserted-by":"publisher","first-page":"59","DOI":"10.18773\/austprescr.2017.013","volume":"40","author":"M Purvey","year":"2017","unstructured":"Purvey, M. & Allen, G. Managing acute pulmonary oedema. Aust. Prescr. 40, 59\u201363 (2017).","journal-title":"Aust. Prescr."},{"key":"486_CR189","doi-asserted-by":"publisher","first-page":"124","DOI":"10.14797\/ZKUT3813","volume":"17","author":"J Sugarman","year":"2021","unstructured":"Sugarman, J. & Weatherald, J. Management of pulmonary hypertension due to chronic lung disease. Methodist Debakey Cardiovasc. J. 17, 124\u2013133 (2021).","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"486_CR190","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1183\/09031936.00015608","volume":"32","author":"R Chaouat","year":"2008","unstructured":"Chaouat, R. & Naeije, E. W. Pulmonary hypertension in COPD. Eur. Respir. J. 32, 1371\u20131385 (2008).","journal-title":"Eur. Respir. J."},{"key":"486_CR191","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","volume":"7","author":"SD Nathan","year":"2019","unstructured":"Nathan, S. D. et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir. Med. 7, 780\u2013790 (2019).","journal-title":"Lancet Respir. Med."},{"key":"486_CR192","first-page":"CD012621","volume":"1","author":"H Barnes","year":"2019","unstructured":"Barnes, H., Brown, Z., Burns, A. & Williams, T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst. Rev. 1, CD012621 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"486_CR193","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman, A. et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N. Engl. J. Med. 384, 325\u2013334 (2021).","journal-title":"N. Engl. J. Med."},{"key":"486_CR194","doi-asserted-by":"publisher","first-page":"2002828","DOI":"10.1183\/13993003.02828-2020","volume":"57","author":"M Delcroix","year":"2021","unstructured":"Delcroix, M. et al. ERS statement on chronic thromboembolicpulmonary hypertension. Eur. Respir. J. 57, 2002828 (2021).","journal-title":"Eur. Respir. J."},{"key":"486_CR195","unstructured":"European Lung Foundation. Diagnosing and treating pulmonary hypertension: understanding the professional guidelines. European Lung Foundation https:\/\/europeanlung.org\/wp-content\/uploads\/2022\/09\/Diagnosing-and-treating-PH-Understanding-the-professional-guidelines-EN.pdf (2023)."},{"key":"486_CR196","first-page":"160111","volume":"26","author":"J David","year":"2007","unstructured":"David, J. et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur. Respir. Rev. 26, 160111 (2007).","journal-title":"Eur. Respir. Rev."},{"key":"486_CR197","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski, H. et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322\u2013329 (2002).","journal-title":"N. Engl. J. Med."},{"key":"486_CR198","unstructured":"European Medicines Agency. Annex 1: Summary of product characteristics. Trepulmix. EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trepulmix-epar-product-information_en.pdf (2020)."},{"key":"486_CR199","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.healun.2022.05.002","volume":"41","author":"CB Wiedenroth","year":"2022","unstructured":"Wiedenroth, C. B. et al. Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: impact on the outcome. J. Heart Lung Transpl. 41, 1086\u20131094 (2022).","journal-title":"J. Heart Lung Transpl."},{"key":"486_CR200","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1038\/jp.2016.46","volume":"36","author":"J Gien","year":"2016","unstructured":"Gien, J. & Kinsella, J. P. Management of pulmonary hypertension in infants with congenital diaphragmatic hernia. J. Perinatol. 36, S28\u2013S31 (2016).","journal-title":"J. Perinatol."},{"key":"486_CR201","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.amjcard.2010.03.048","volume":"106","author":"J Alkon","year":"2010","unstructured":"Alkon, J. et al. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am. J. Cardiol. 106, 430\u2013436 (2010).","journal-title":"Am. J. Cardiol."},{"key":"486_CR202","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1378\/chest.13-0636","volume":"145","author":"MP Mullen","year":"2014","unstructured":"Mullen, M. P. et al. Quality of life and parental adjustment in pediatric pulmonary hypertension. Chest 145, 237\u2013244 (2014).","journal-title":"Chest"},{"key":"486_CR203","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/2045-8932.109919","volume":"3","author":"G Strange","year":"2013","unstructured":"Strange, G. et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the Delay study. Pulm. Circ. 3, 89\u201394 (2013).","journal-title":"Pulm. Circ."},{"key":"486_CR204","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1378\/chest.10-1166","volume":"140","author":"LM Brown","year":"2011","unstructured":"Brown, L. M. et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 140, 19\u201326 (2011).","journal-title":"Chest"},{"key":"486_CR205","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","volume":"107","author":"S Rich","year":"1987","unstructured":"Rich, S. et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107, 216\u2013223 (1987).","journal-title":"Ann. Intern. Med."},{"key":"486_CR206","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/imj.12321","volume":"44","author":"G Strange","year":"2014","unstructured":"Strange, G. et al. Pulmonary hypertension and breathlessness: is it a combination we can ignore? Intern. Med. J. 44, 114\u2013123 (2014).","journal-title":"Intern. Med. J."},{"key":"486_CR207","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12257","volume":"13","author":"F Arogundade","year":"2023","unstructured":"Arogundade, F. et al. The MRC Dyspnoea Scale and mortality risk prediction in pulmonary arterial hypertension: a retrospective longitudinal cohort study. Pulm. Circ. 13, e12257 (2023).","journal-title":"Pulm. Circ."},{"key":"486_CR208","first-page":"4983","volume":"25","author":"K Sarzynska","year":"2021","unstructured":"Sarzynska, K. et al. Quality of life of patients with pulmonary arterial hypertension: a meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 25, 4983\u20134998 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"486_CR209","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41569-020-0332-9","volume":"17","author":"S Stewart","year":"2020","unstructured":"Stewart, S. et al. The challenge of an expanded therapeutic window in pulmonary hypertension. Nat. Rev. Cardiol. 17, 195\u2013197 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"486_CR210","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11136-005-3513-4","volume":"15","author":"SP McKenna","year":"2006","unstructured":"McKenna, S. P. et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual. Life Res 15, 103\u2013115 (2006).","journal-title":"Qual. Life Res"},{"key":"486_CR211","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4244\/AIJ-D-21-00033","volume":"8","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: long-term mortality after PADN stratified by functional class. AsiaIntervention 8, 58\u201368 (2022).","journal-title":"AsiaIntervention"},{"key":"486_CR212","doi-asserted-by":"publisher","first-page":"106801","DOI":"10.1016\/j.rmed.2022.106801","volume":"196","author":"R Gupta","year":"2022","unstructured":"Gupta, R. et al. The six-minute walk test in sarcoidosis associated pulmonary hypertension: results from an international registry. Respir. Med. 196, 106801 (2022).","journal-title":"Respir. Med."},{"key":"486_CR213","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni, J. W. et al. The PedsQL: measurement model for the pediatric quality of life inventory. Med. Care 37, 126\u2013139 (1999).","journal-title":"Med. Care"},{"key":"486_CR214","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.3390\/ijms231710001","volume":"23","author":"AJ Shah","year":"2022","unstructured":"Shah, A. J. et al. Molecular pathways in pulmonary arterial hypertension. Int. J. Mol. Sci. 23, 10001 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"486_CR215","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12184","volume":"13","author":"E Louw","year":"2023","unstructured":"Louw, E. et al. The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients. Pulm. Circ. 13, e12184 (2023).","journal-title":"Pulm. Circ."},{"key":"486_CR216","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa0708629","volume":"359","author":"AO Mocumbi","year":"2008","unstructured":"Mocumbi, A. O. et al. A population study of endomyocardial fibrosis in a rural area of Mozambique. N. Engl. J. Med. 359, 43\u201349 (2008).","journal-title":"N. Engl. J. Med."},{"key":"486_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2022.09.015","volume":"42","author":"J Weatherald","year":"2023","unstructured":"Weatherald, J. et al. Priorities for pulmonary hypertension research: a James Lind Alliance priority setting partnership. J. Heart Lung Transpl. 42, 1\u20136 (2023).","journal-title":"J. Heart Lung Transpl."},{"key":"486_CR218","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1086\/678507","volume":"4","author":"DG Papamatheakis","year":"2014","unstructured":"Papamatheakis, D. G. et al. Schistosomiasis-associated pulmonary hypertension. Pulm. Circ. 4, 596\u2013611 (2014).","journal-title":"Pulm. Circ."},{"key":"486_CR219","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/zph.12874","volume":"68","author":"HT Menghistu","year":"2021","unstructured":"Menghistu, H. T. et al. Neglected tropical zoonotic diseases in Tigray region, northern Ethiopia: spatial distribution and trend analysis of rabies, tuberculosis, schistosomiasis, and visceral leishmaniasis in humans. Zoonoses Public Health 68, 823\u2013833 (2021).","journal-title":"Zoonoses Public Health"},{"key":"486_CR220","unstructured":"World Health Organization. Global tuberculosis report 2021. WHO https:\/\/www.who.int\/publications\/i\/item\/9789240037021 (2021)."},{"key":"486_CR221","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1164\/rccm.200704-541OC","volume":"177","author":"O Sitbon","year":"2008","unstructured":"Sitbon, O. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 177, 108\u2013113 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"486_CR222","unstructured":"WHO. HIV: Global situation and trends. WHO https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids (2022)."},{"key":"486_CR223","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004843","volume":"4","author":"A Dzudie","year":"2014","unstructured":"Dzudie, A. et al. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open 4, e004843 (2014).","journal-title":"BMJ Open"},{"key":"486_CR224","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5830\/CVJA-2018-007","volume":"29","author":"A Dzudie","year":"2018","unstructured":"Dzudie, A. et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovasc. J. Afr. 29, 208\u2013212 (2018).","journal-title":"Cardiovasc. J. Afr."},{"key":"486_CR225","doi-asserted-by":"publisher","first-page":"a017871","DOI":"10.1101\/cshperspect.a017871","volume":"26","author":"J Bruchfeld","year":"2015","unstructured":"Bruchfeld, J., Correia-Neves, M. & K\u00e4llenius, G. Tuberculosis and HIV coinfection. Cold Spring Harb. Perspect. Med. 26, a017871 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"486_CR226","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ijid.2020.10.088","volume":"102","author":"P Patel","year":"2021","unstructured":"Patel, P. et al. Association of schistosomiasis and HIV infections: a systematic review and meta-analysis. Int. J. Infect. Dis. 102, 544\u2013553 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"486_CR227","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7196\/SAMJ.2017.v107i10.12321","volume":"107","author":"LN Aminde","year":"2017","unstructured":"Aminde, L. N. et al. Gender disparities in pulmonary hypertension at a tertiary centre in Cameroon. S. Afr. Med. J. 107, 892\u2013899 (2017).","journal-title":"S. Afr. Med. J."},{"key":"486_CR228","doi-asserted-by":"publisher","first-page":"ofac604","DOI":"10.1093\/ofid\/ofac604","volume":"9","author":"F Thienemann","year":"2022","unstructured":"Thienemann, F. et al. Long-term follow-up of human immunodeficiency virus-associated pulmonary hypertension: clinical features and survival outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO). Open Forum Infect. Dis. 9, ofac604 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"486_CR229","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/S0140-6736(22)01601-4","volume":"400","author":"J Weatherald","year":"2022","unstructured":"Weatherald, J. et al. The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet 400, 1884\u20131898 (2022).","journal-title":"Lancet"},{"key":"486_CR230","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/S0735-1097(98)00162-4","volume":"31","author":"BM Weiss","year":"1998","unstructured":"Weiss, B. M. et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J. Am. Coll. Cardiol. 31, 1650\u20131657 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"486_CR231","first-page":"3165","volume":"39","author":"V Regitz-Zagrosek","year":"2018","unstructured":"Regitz-Zagrosek, V. et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur. Respir. J. 39, 3165\u20133241 (2018).","journal-title":"Eur. Respir. J."},{"key":"486_CR232","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejogrb.2020.08.028","volume":"253","author":"N Jha","year":"2020","unstructured":"Jha, N. et al. Pulmonary hypertension and pregnancy outcomes: systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 253, 108\u2013116 (2020).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"486_CR233","doi-asserted-by":"publisher","first-page":"100194","DOI":"10.1016\/j.clinsp.2023.100194","volume":"78","author":"C Lv","year":"2023","unstructured":"Lv, C. et al. Maternal and fetal\/neonatal outcomes of pregnancies complicated by pulmonary hypertension: a retrospective study of 154 patients. Clinics 78, 100194 (2023).","journal-title":"Clinics"},{"key":"486_CR234","first-page":"3848","volume":"40","author":"J Roos-Hesselink","year":"2019","unstructured":"Roos-Hesselink, J. et al. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur. Respir. J. 40, 3848\u20133855 (2019).","journal-title":"Eur. Respir. J."},{"key":"486_CR235","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ejhf.594","volume":"18","author":"K Sliwa","year":"2016","unstructured":"Sliwa, K. et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur. J. Heart Fail. 18, 1119\u20131128 (2016); erratum 19, 439 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"486_CR236","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.3390\/ijerph20054625","volume":"20","author":"K Bara\u0144ska-Pawe\u0142czak","year":"2023","unstructured":"Bara\u0144ska-Pawe\u0142czak, K. et al. Pregnancy in patients with pulmonary arterial hypertension in light of new ESC guidelines on pulmonary hypertension. Int. J. Environ. Res. Public Health 20, 4625 (2023).","journal-title":"Int. J. Environ. Res. Public Health"}],"updated-by":[{"DOI":"10.1038\/s41572-024-00493-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000}}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-023-00486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-023-00486-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-023-00486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T06:07:17Z","timestamp":1705471637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-023-00486-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":236,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1038\/s41572-023-00486-7","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"27 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41572-024-00493-2","URL":"https:\/\/doi.org\/10.1038\/s41572-024-00493-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. declares institutional, speaker, consultant or steering committee fees from Aerovate, Altavant, AOP Orphan, Bayer, Ferrer, Janssen (Actelion), MSD (Acceleron) and United Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}